Cary Savitch
Infectious Disease · Ventura, CANPI 1518971084
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 31.2% of the total. Reporting peaked in 2019 at $2,385 and has fallen 58.4% since, to $993 in 2024.
Across 80 payments — averaging $98.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$849
- Merck$697
- Bristol Myers Squibb$545
- Eisai Inc.$334
- E.r. Squibb & Sons, L.L.C.$308
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,828100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $2,446 |
| Lilly USA, LLC | 7 | $849 |
| Merck | 10 | $697 |
| Bristol Myers Squibb | 5 | $545 |
| Eisai Inc. | 3 | $334 |
| E.r. Squibb & Sons, L.L.C. | 3 | $308 |
| Regeneron Healthcare Solutions, Inc. | 2 | $248 |
| GSK | 2 | $225 |
| Amgen(2 entities) | 2 | $217 |
| Genentech USA, Inc. | 2 | $210 |
| Sanofi | 2 | $193 |
| AbbVie | 4 | $166 |
| Janssen Products, LP | 1 | $125 |
| Beigene USA, Inc. | 1 | $125 |
| Incyte Corporation | 1 | $125 |
| GE HealthCare | 1 | $103 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $101 |
| Clovis Oncology, Inc. | 1 | $100 |
| Genmab U.S., Inc. | 1 | $98 |
| Bayer | 1 | $98 |
| Sun Pharmaceutical Industries Inc. | 1 | $98 |
| Daiichi Sankyo Inc. | 1 | $95 |
| Progenics Pharmaceuticals, Inc. | 1 | $85 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $70 |
| Sobi, Inc | 1 | $70 |
| Paratek Pharmaceuticals, Inc. | 2 | $62 |
| Gilead | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,840 in reported general payments places this provider in the 85th percentile of 856 infectious disease providers in California.
Other infectious disease in Ventura
- Claire PomeroySacramento$2.6M
- Javeed SiddiquiRoseville$1.5M
- George SakoulasSan Diego$902K
- Arthur JengSylmar$766K
- James McKinnellTorrance$762K
- Jay GladsteinLos Angeles$657K
- Tulika SinghOrange$654K
- Otto YangLos Angeles$472K
- Franco FelizartaBakersfield$440K
- Shawn HasslerSan Francisco$433K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.